Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

Using the approved multiple sclerosis therapy Kesimpta helps keep relapsing MS stable over time for most adults, a real-world ...

CHARLOTTE — The investigational oral Bruton tyrosine kinase inhibitor (BTKi) fenebrutinib significantly outperformed teriflunomide on relapse and MRI outcomes, marking the first potential win ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology. Izanne Roos, M.B.Ch.B., ...

Antibiotic resistance continues to push modern medicine into dangerous territory. In hospitals around the world, infections once treated easily now survive some of the strongest drugs available.

A breakthrough in monkey malaria research could help scientists diagnose and treat a relapsing form of human malaria. A breakthrough in monkey malaria research by two University of Otago scientists ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

The appraisal committee considered evidence submitted by Novartis, and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...